2nd Quarter - Report

TIBER CREEK GROUP for MERCK & CO., INC

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to drug pricing, reimbursement for prescription drugs, and the pharmaceutical supply chain; H.R. 6833/S. 3700 - Affordable Insulin Now Act; S.2199 - Insulin Price Reduction Act; S. 4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022; H.R. 7667 - Food and Drug Amendments of 2022; Issues related to the deployment of COVID treatments.

LobbyistCovered position, as disclosed
JOHN MICHAEL GONZALEZ —
JONATHON JONES —
COREY MALMGREN —
ANDREW MCKECHNIE —

Contacted: SENATE; Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES

Bills named: S. 2199 (117th), H.R. 6833 (117th), S. 4348 (117th), H.R. 7667 (117th), S. 3700 (117th)

Medicare/Medicaid MMM

H.R. 5376 - Build Back Better, Subtitle J, issues relating to Medicare Part D and Part B Pricing Reform; Issues related to capping out-of-pocket costs.

LobbyistCovered position, as disclosed
JOHN MICHAEL GONZALEZ —
JONATHON JONES —
COREY MALMGREN —
ANDREW MCKECHNIE —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 5376 (117th)

Trade (domestic/foreign) TRD

Issues relating to Intellectual Property protections for Covid-19 treatments and vaccines.

LobbyistCovered position, as disclosed
JOHN MICHAEL GONZALEZ —
COREY MALMGREN —

Contacted: HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.